glucan projects

 project 1 - Clinical trials:

The role of glucan in the stimulation of immune reactions is well established. In our trials, we focused on the effects of orally administered glucan on nonspecific immunity of children with chronic respiratory problems. A randomized, double-blind, placebo-controlled trial compared β-glucan #300 and placebo in children. Subjects were randomly assigned to groups which were blinded to intervention. During the intervention period, subject consumed 100 mg/d of β-glucan or placebo. Both glucan and placebo capsules looked identical. The whole study was performed at the Sanatorium for Respiratory Diseases EDEL (Zlate Hory, Czech Republic), where the children were enrolled in a 30-day trial. The study was approved by the Ethics committee of the Public Health Institute and Sanatorium EDEL. This study was performed in agreement with Helsinki declaration (revised version 2000.09.01) and in full agreement of rules for clinical testing for the Czech Republic. Parental consent was given in all cases. Throughout the entire stay, the children were under regular supervision by medical staff. We found a significant increase in the production of changes in production of lysozyme, CRP, calprotectin and salivary immunoglobulins in glucan-treated children. Based on our data we can conclude that b-glucan treatment has positive stimulatory effect on mucosal immunity and that glucan administration might be considered as a highly promising and at the same time inexpensive method in the treatment of chronic respiratory problems in children.

project 2:

This project is focused on evaluation of the immunostimulating effects of glucan, with specific attention on commercial material. Recently, there has been a significant backslash against overuse of synthetic drugs that has lead to increased interest in natural molecules and treatments. In this regard, substances with significant immunomodulatory properties are particularly interesting. As natural molecule, glucan might suffer from significant batch-to-batch variability diminishing its use in medicine. Being able to recognize most active glucan opens the door to clinical use.

project 3:

It is well established that glucans enhance the efficacy of anti-cancer and anti-infections immunotheraphy, both in clinical and experimental conditions. However, the considerable variations among batches of natural glucan in molecular weight, branching frequency as well as linkage to chitins and mannoproteins make the clinical applications of natural glucan questionable. The future might be in the use of small synthetic oligosaccharides prepared on basis of natural glucans. The recent studies strongly suggest the possibility of small chemical changes in the structure of these oligoglucans oriented towards their improved biological activities.

More information about glucan

commercial use of glucan

 

       HUMANS

 

 

  • Success requires anti-tumor antibody that generates iC3b on tumorss
  • Patients with breast cancer generate antibody response and will respond to glucan alone as long the tumors are targeted with antibody and iC3
  • Humanized antibodies such as Herceptin and Rituximad are good targets for combined therapy with glucan
  • Even tumors that have lost MHC class I might be targets
  • May function to reduce myelosuppression caused by chemo- or radiation therapy

1
  
animals

 

 

  • Success requires anti-tumor antibody that generates iC3b on tumorss
  • Patients with breast cancer generate antibody response and will respond to glucan alone as long the tumors are targeted with antibody and iC3
  • Humanized antibodies such as Herceptin and Rituximad are good targets for combined therapy with glucan
  • Even tumors that have lost MHC class I might be targets
  • May function to reduce myelosuppression caused by chemo- or radiation therapy

Back to Home